Arch Therapeutics Inc. (ARTH) 0.2200 $ARTH Global Wound

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Arch Therapeutics Inc. (ARTH) 0.2200 $ARTH

Global Wound Closure Devices Pipeline Review 2015
M2 - Tue Apr 28, 3:29AM CDT
Research and Markets (http://www.researchandmarkets.com/research/48sc22/wound_closure) has announced the addition of the "Wound Closure Devices - Pipeline Review, 2015" report to their offering. The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key wound closure devices pipeline products. Scope: - Extensive coverage of the Wound Closure Devices products under development - The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities - The report reviews the major players involved in the development of Wound Closure Devices and list all their pipeline projects - The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage - The report provides key clinical trial data of ongoing trials specific to pipeline products - Recent developments in the segment / industry The report enables you to: - Formulate significant competitor information, analysis, and insights to improve R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of Wound Closure Devices under development - Develop market-entry and market expansion strategies - Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline - In-depth analysis of the product's current stage of development, territory and estimated launch date Companies Featured: - 3-D Matrix, Ltd. - Advanced Medical Solutions Group plc - Anika Therapeutics, Inc. - Arch Therapeutics Inc. - Arsenal Medical, Inc. - Baxter International Inc. - Bergen Medical Products, Inc. - Beth Israel Deaconess Medical Center, Inc. - Boston Scientific Corporation - Boston University - C. R. Bard, Inc. - Cellphire, Inc. - Clemson University - Emory University - Endomedix Incorporated - Entegrion, Inc. - Floralis S.A.S. - Johns Hopkins University - KeraNetics, LLC - Kitotech Medical, Inc. - Kuros Biosurgery AG - Laser Tissue Welding, Inc. - LifeBond Ltd. - Medical Adhesive Revolution GmbH - Medisse BV - Medtronic plc - OptMed, Inc. - Remedium Technologies Inc. - University of Akron - VitaThreads, LLC - Vivostat A/S - Vivostat A/S - Ongoing Clinical Trials Overview - Xcede Technologies, Inc. For more information visit http://www.researchandmarkets.com/research/48...nd_closure
BSX: 17.85 (-0.06), MDT: 76.42 (+0.16), BAX: 69.36 (+0.32), ANIK: 34.55 (-0.90)

Arch Therapeutics' AC5(TM) Compared Favorably vs. Commercially Available Combination Hemostat in Animal Study
Marketwired - Thu Apr 16, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced that an independent third party has obtained favorable data from an animal study that compared the hemostatic activity of AC5 with a commercially available branded hemostat consisting of a flowable gelatin combined with thrombin.

Arch Therapeutics Announces Favorable Preclinical Data From an Independent Study of AC5 Surgical Hemostatic Device(TM) Versus a Popular Fibrin Sealant
Marketwired - Tue Apr 14, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced that an independent third party has obtained favorable data from a preclinical animal study that compared the hemostatic activity of AC5 with a popular and commercially available branded fibrin sealant that is indicated for use in controlling bleeding.

Arch Therapeutics Announces Favorable Preclinical Data from an Independent Study of AC5 Surgical Hemostatic Device(TM) Versus a Popular Cellulose-Based Hemostatic Agent
Marketwired - Wed Mar 25, 6:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, announced that an independent third party has obtained favorable data from a preclinical animal study that compared the hemostatic activity of AC5 with a popular and commercially available branded absorbable hemostatic agent.

Arch Therapeutics Announces Positive Safety Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Toxicity Studies
Marketwired - Mon Mar 23, 7:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)) for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, obtained additional favorable preclinical data from two (2) planned standardized medical device safety studies in which AC5 was assessed for toxicity to cells and for contamination from pyrogens (toxins that cause fever) produced by bacterial cells. The tests are major components of the panel of biocompatibility testing that medical devices must typically complete successfully prior to use in humans.

Nanomedicine: Nanotechnology, Biology, and Medicine Publishes Preclinical Data on Arch Therapeutics' AC5 Surgical Hemostatic Device(TM)
Marketwired - Thu Feb 19, 7:57AM CST
Positive data from an independent third-party research group study sponsored by Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), was published in the peer-reviewed journal Nanomedicine: Nanotechnology, Biology, and Medicine. The results in the manuscript, titled "AC5 Surgical Hemostat(TM) as an Effective Hemostatic Agent in an Anticoagulated Rat Liver Punch Biopsy Model," show that AC5(TM) is agnostic to the presence of the anticoagulant heparin in animals. The abstract can be accessed online here: http://www.nanomedjournal.com/article/S1549-9...8/abstract.

The British Standards Institution Classifies Arch Therapeutics' AC5(TM) as a Medical Device Within the European Union
Marketwired - Tue Feb 17, 7:03AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , a medical device company and developer of the AC5 Surgical Hemostatic Device(TM) (AC5(TM)), a novel product aimed at controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, has received confirmation from The British Standards Institution (BSI), a Notified Body in the European Union (EU), that AC5 fulfills the definition of a medical device within the EU and will be classified as such in consideration for CE mark designation. Eventually obtaining the CE mark for AC5 would allow the Company to sell the product within the EU.

Arch Therapeutics Obtains Additional Positive Results for AC5 Surgical Hemostatic Device(TM) in Preclinical Safety Study
Marketwired - Tue Jan 13, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), obtained positive results when AC5(TM) was subjected to a standardized medical device test for irritation potential. The irritation test in animals is a major component of the International Organization for Standardization's (ISO) required panel of biocompatibility testing necessary for medical devices prior to use in humans. AC5 is a unique development-stage hemostasis product being evaluated to control bleeding and fluid loss in order to provide faster and safer surgical and interventional care.

Arch Therapeutics Announces Positive Results for AC5 Surgical Hemostatic Device(TM) in Biochemical and Cell Function Safety Studies
Marketwired - Tue Jan 06, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), obtained positive results from preclinical tests in which AC5(TM) was subjected to a battery of high-throughput in vitro safety assessments for biological interactions in standardized testing panels of receptors on the surface of cells and protein kinase enzymes inside cells. These receptors and enzymes represent important biochemical "switches," and interactions with them could indicate biological activity with the potential for toxicity. AC5 is a unique development-stage hemostasis product being evaluated to control bleeding and fluid loss in order to provide faster and safer surgical and interventional care.

Arch Therapeutics to Present at The Biotech Showcase(TM) 2015 Conference on January 14th 2015
Marketwired - Wed Dec 17, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), announced that it would be featured as a presenting company at The Biotech Showcase(TM) 2015 Conference on Wednesday, January 14, 2015 at 11:00 AM PST. The conference will be held at the Parc 55 Wyndham Hotel, located at Union Square, San Francisco, California.

ARTH Developing Next Generation Biopharma Product in a $5 Billion Market with Plans for Product Launch in 2015
M2 - Wed Dec 10, 7:13AM CST
ARTH's Flagship product AC5(TM) stops bleeding promptly, even in the presence of blood thinners based on animal data to date. Unlike many competitive products, it conforms to irregular wound geometry, allows for normal healing, and helps maintain a clear field of vision.

Arch Therapeutics to Present at LD Micro Main Event on December 4th 2014
Marketwired - Mon Nov 24, 3:00PM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), announced that it would be featured as a presenting company at the LD Micro conference on Thursday, December 4, 2014 at 12:00 PM EST. The conference will be held at the Luxe Sunset Hotel in Bel Air, California.

Arch Therapeutics Reports Positive Preclinical Data from Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated with Brilinta(R) (ticagrelor)
Marketwired - Wed Nov 19, 3:26PM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostat Device(TM), announced that an independent third party has obtained positive data from a preclinical study assessing the use of AC5(TM) in animals that had been treated with orally administered therapeutic doses of the blood thinner ticagrelor, which is currently marketed under the brand name Brilinta(R). The results of the study are consistent with separate data obtained from two recently completed preclinical studies in which AC5 quickly stopped bleeding from surgical wounds created in rats following treatment with clinically relevant doses of the anticoagulant medication heparin; and another preclinical study which reported similar results with respect to the antiplatelet medications Plavix(R) (clopidogrel) and aspirin when used individually and in combination. Anticoagulant and antiplatelet medications are commonly referred to as "blood thinners."

Arch Therapeutics Will Present at Two Investor Conferences in November
Marketwired - Mon Nov 10, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM), announced that it would be featured as a presenting company at two conferences in November: SeeThruEquity Microcap Investor Conference and Drexel Hamilton Micro-Cap Investor Forum.

Arch Therapeutics Reports Positive Preclinical Data From Study of AC5 Surgical Hemostatic Device(TM) in Animals Treated With the Antiplatelet Medications Plavix(R) (Clopidogrel) and Aspirin
Marketwired - Thu Nov 06, 7:57AM CST
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostat Device (TM), announced that an independent third-party research group has obtained positive data from a preclinical study assessing the use of AC5(TM) in animals that had been treated with therapeutic doses of the antiplatelet medications Plavix(R) (clopidogrel) and aspirin alone and in combination. The results of the study are consistent with recent data obtained from two previous preclinical studies, in which AC5 quickly stopped bleeding from surgical wounds created in rats following treatment with clinically relevant doses of the anticoagulant medication heparin. Antiplatelet and anticoagulant medications are commonly referred to as "blood thinners."

SeeThruEquity Initiates Research Coverage on Arch Therapeutics with a Target Price of $1.50
ACCESSWIRE - Wed Nov 05, 8:06AM CST
New York, NY / ACCESSWIRE / November 5, 2014 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has initiated coverage on Arch Therapeutics, Inc. (OTCQB: ARTH) with a price target of $1.50.

Arch Therapeutics Negotiating a Collaboration Agreement With CURAM Centre for Research in Medical Devices
Marketwired - Thu Oct 23, 7:16AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostat(TM), announced today that it is negotiating a potential collaboration agreement with CURAM Centre for Research in Medical Devices ("CURAM" . CURAM is a major new national research center being established at the National University of Ireland Galway (NUIG) in Galway, Ireland, as part of a six-year grant from the Irish government, which was announced this week. Proceeds, which are expected to be released by the Irish government in January 2015, are intended to fund collaborative work performed by CURAM and its planned industry partners which, subject to the execution of a definitive collaboration agreement, would include Arch. Industry partners, which will benefit by provision of highly skilled personnel, significant grant funding, and available infrastructure support, will provide capital to match a portion of the government funds designated for their respective R&D programs.

Arch Therapeutics Will Present at the Livingston Securities Life Sciences Stakeholders Summit on October 1, 2014
Marketwire - Tue Sep 30, 7:57AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostat(TM), announced that it will be featured as a presenting company at the 7th Annual Livingston Securities Life Sciences Stakeholders Summit on October 1, 2014 at the Cira Center in Philadelphia, PA.

Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th International Conference on Neuroprotective Agents on September 29
Marketwire - Tue Sep 23, 7:51AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) for potential use in bleeding during surgery, announces that co-founder and inventing scientist Dr. Rutledge Ellis-Behnke will present his work using AC5 Surgical Hemostat(TM) at the 12th International Conference on Neuroprotective Agents (ICNA). The ICNA is being held September 29 - October 1, 2014, at the Boar's Head Inn, Charlottesville, VA.

Arch Therapeutics Co-Founder Rutledge Ellis-Behnke to Speak at 12th Annual Current Issues in Medicine, Biotech and Pharma Conference on September 18
Marketwire - Tue Sep 16, 10:21AM CDT
Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company" , developer of the AC5 Surgical Hemostatic Device(TM) for potential use in bleeding during surgery, announces that co-founder, inventing scientist and advisor Dr. Rutledge Ellis-Behnke will present research involving AC5(TM) at the 12th Annual Current Issues in Medicine, Biotech and Pharma Conference at Rensselaer Polytechnic Institute in Troy, NY on Thursday, September 18.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 7

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Tips for a Dementia-Friendly Thanksgiving Gathering

Updated Category News Views 36

Thanksgiving's supposed to bring families round the table, right? But toss a few knuckleheads together, add a pinch of dementia, and suddenly it's like throwing dice at a craps table. The American Speech-Language-Hearing Association (ASHA) reckons they've got tricks up their sleeve to keep the holiday from unraveling. The Thanksgiving Reality Check The hustle, bustle, and...

Continue Reading
Galileo's Robot Dog Takes Charge in Polish Warehouses

Updated Category News Views 146

Robotic Innovation Makes Waves in Europe You ever think you’d see the day when a dog—albeit a robotic one—takes the night shift at a warehouse? Well, here we are. Galileo Robotics has unleashed its C1-W robot dog in Poznan, Poland, and it's more than just a fancy tech gimmick. This thing's got potential, bridging gaps left wide open by human labor shortages and...

Continue Reading
YYForce's Strategic Play: Robotics and AI Expansion

Updated Category News Views 28

Innovation Meets Pragmatism at YYForce There's a new bout of excitement brewing over at YYForce Inc. (NASDAQ: YFOR), if the latest announcements are anything to go by. The Singapore-based AI-enabled workforce dynamo is laying out priorities like a general plotting a campaign—pragmatic, strategic, and with a keen eye on the bottom line. Aiming for a Technological Edge In...

Continue Reading
Orangetheory Adds NASM Training for Coaching Edge

Updated Category News Views 36

A Shift in Coaching Standards Ever seen a fitness brand tilt towards a change so fast it leaves you slack-jawed? Well, here we go with Orangetheory Fitness pushing its chips all in with NASM-certified coaches geared for the GLP-1 era. A bold move? Sure, but they aim to become trendsetters instead of just another player in the fitness game. The Impact of NASM Certification...

Continue Reading
Sasol AGM Resolutions Passed in One Swift Swing

Updated Category News Views 102

Sasol's AGM Delivers Smooth Sailing for Shareholders Can't say I'm surprised, but Sasol's annual general meeting on the 13th of November went off without a hitch—unless, of course, you're one of those folks who just loves fireworks at these gatherings. The entire set of resolutions danced through with a resounding "Aye," making it one heck of a day for anyone banking on...

Continue Reading
Mall of America Strives for World Record This Black Friday

Updated Category News Views 111

History in the Making at Mall of America Yeah, it seems these folks are not just about shopping anymore. The Mall of America is aiming to set the bar high this Black Friday, eyeing a GUINNESS WORLD RECORDS title for the most people holding up the same shopping bag all at once. Imagine a thousand people, synchronized like a flash mob—only with shopping bags instead of...

Continue Reading
SahajMobile's $25M Boost: Impact on Bangladesh Market

Updated Category News Views 42

Untapped Digital Frontier in Bangladesh There's an undeniable buzz around SahajMobile's recent $25 million credit facility, and it's one worth dissecting. This shot of capital, lined up with ALMA as part of SahajMobile’s Series A gamble, is setting the stage for a real shuffle in Bangladesh's digital landscape. Plugging into a Market Gap Ever since it hit the ground...

Continue Reading
Lululemon Faces Class Action over Alleged Missteps

Updated Category News Views 13

Trouble Brewing for Lululemon Y'ever get that gut feeling when something doesn't smell right? Well, Lululemon Athletica (NASDAQ: LULU) investors are probably feeling that now. A class action's kicking up dust over what some are saying was a downright bumpy ride. The brainiacs at Robbins LLP urge those who've lost bucks riding the LULU train to step forward ahead of the...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 319

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading

Top 5 Most Recently Viewed Articles

Ohmyhome Prepares to Share Exciting Q3 2024 Growth Insights

Updated Category News Views 84

Ohmyhome Set to Unveil Q3 2024 Growth Insights As a leading property technology platform, Ohmyhome Ltd. (NASDAQ: OMH) has established itself as a prominent player in the real estate market. The company specializes in offering comprehensive solutions ranging from brokerage, renovation, and management services for properties in the region. As consumers increasingly look for...

Continue Reading
Innovative Partnership Between TotalEnergies and Emerson Energizes Industrial Data Solutions

Updated Category News Views 344

Transforming Industrial Data Management TotalEnergies and Emerson are uniting to implement extensive industrial data collection solutions across TotalEnergies' operational landscape. This exciting partnership aims to harness continuous and real-time data collection to significantly enhance operational efficiency, energy utilization, and environmental performance at...

Continue Reading
Doré Copper and Cygnus Metals Forge New Mineral Giant Together

Updated Category News Views 114

Doré Copper and Cygnus Metals Join Forces for a Stronger Future Doré Copper Mining Corp. (TSXV: DCMC; OTCQB: DRCMF; FRA: DCM) is thrilled to announce an exciting development. The company has entered into a definitive arrangement agreement with Cygnus Metals Limited (ASX: CY5) to merge their businesses. This is not just any merger; it's a merger of equals that aims to...

Continue Reading
G Mining Ventures Unveils Key Corporate Developments

Updated Category News Views 132

G Mining Ventures Unveils Key Corporate Developments G Mining Ventures Corp. has been making headlines as it continues to expand its influence in the mining industry. The company is dedicated to innovating its strategies while navigating the complexities of market dynamics. By focusing on sustainable practices and operational efficiency, G Mining Ventures aims to enhance...

Continue Reading
Neutrinos Launches Innovative Suite to Transform Insurance Underwriting

Updated Category News Views 489

Neutrinos Launches Innovative Suite for Underwriting Automation In a transformative leap forward for the insurance industry, Neutrinos has introduced its Underwriting Automation Suite, tailored specifically for life, annuities, and health insurance. This cutting-edge tool aims to streamline underwriting workflows, enhance risk assessments, and ultimately elevate...

Continue Reading